These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Author: Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.
    Journal: Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726.
    Abstract:
    OBJECTIVE: Duloxetine is a serotonergic noradrenergic reuptake inhibitor with demonstrated efficacy in each of three independent studies for treatment of adults with generalized anxiety disorder (GAD). A pooled dataset from all completed trials is provided here to show the most likely clinical outcomes associated with duloxetine treatment for GAD. RESEARCH DESIGN AND METHODS: Data were summed at the individual patient level from three double-blind, placebo-controlled trials of duloxetine treatment: two were 10-week flexible-dose 60-120 mg/day and one was 9-week fixed dose 60 or 120 mg/day. Inclusion/exclusion criteria were consistent across studies. MAIN OUTCOME MEASURES: Efficacy measures included the Hamilton Anxiety Scale (HAMA) and Sheehan Disability Scale (SDS). Adverse events were queried at every visit in each study. RESULTS: Patients were randomly assigned to duloxetine (n = 668) or placebo (n = 495) treatment. Mean age was 42.4 years; 65% were female. Duloxetine-treated patients improved significantly more from baseline to endpoint on HAMA total score (mean = -11.1 points) compared with placebo-treated patients (mean = -8.0 points, p < or = 0.001). On the SDS global functioning score, patients in the duloxetine group had a mean improvement from baseline of 46% compared with 25% in the placebo group (p < or = 0.001). Nausea was the most common of twelve treatment-emergent adverse events that occurred in the duloxetine group. LIMITATIONS: Pooled studies were not for long-term treatment and did not include patients with comorbid psychiatric conditions. CONCLUSIONS: In this sample of more than 1100 patients, duloxetine was efficacious for reducing anxiety severity and for increasing patients' overall role functioning in GAD.
    [Abstract] [Full Text] [Related] [New Search]